We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Keros Therapeutics, Inc. (KROS - Free Report) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 36.6% loss over the past four weeks.
Earlier this week, the company announced that the global development and commercialization license agreement with Japan’s Takeda related to the advancement of elritercept became effective on Jan. 16, 2025. Elritercept is being developed for treating low blood cell count, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. With the effectiveness of the agreement, Takeda is entitled to make an upfront payment of $200 million to Keros Therapeutics. This might have driven the recent share price rally.
This company is expected to post quarterly loss of $0.93 per share in its upcoming report, which represents a year-over-year change of +30.6%. Revenues are expected to be $105.25 million, up 75078.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Keros Therapeutics, the consensus EPS estimate for the quarter has been revised 2.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on KROS going forward to see if this recent jump can turn into more strength down the road.
Keros Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Revolution Medicines, Inc. (RVMD - Free Report) , finished the last trading session 0.3% lower at $40.16. RVMD has returned -8.3% over the past month.
For Revolution Medicines, the consensus EPS estimate for the upcoming report has changed +3.7% over the past month to -$0.99. This represents a change of +13.2% from what the company reported a year ago. Revolution Medicines currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
Keros Therapeutics, Inc. (KROS - Free Report) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 36.6% loss over the past four weeks.
Earlier this week, the company announced that the global development and commercialization license agreement with Japan’s Takeda related to the advancement of elritercept became effective on Jan. 16, 2025. Elritercept is being developed for treating low blood cell count, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. With the effectiveness of the agreement, Takeda is entitled to make an upfront payment of $200 million to Keros Therapeutics. This might have driven the recent share price rally.
This company is expected to post quarterly loss of $0.93 per share in its upcoming report, which represents a year-over-year change of +30.6%. Revenues are expected to be $105.25 million, up 75078.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Keros Therapeutics, the consensus EPS estimate for the quarter has been revised 2.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on KROS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Keros Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Revolution Medicines, Inc. (RVMD - Free Report) , finished the last trading session 0.3% lower at $40.16. RVMD has returned -8.3% over the past month.
For Revolution Medicines, the consensus EPS estimate for the upcoming report has changed +3.7% over the past month to -$0.99. This represents a change of +13.2% from what the company reported a year ago. Revolution Medicines currently has a Zacks Rank of #2 (Buy).